Psychedelic Law

Quick Reference: Where Things Stand

Last reviewed July 2026. Laws change quickly — always verify the current law in your specific jurisdiction before making decisions. "Decriminalized" never means legal to buy or sell.

Reform is moving quickly in the United States: more than twenty state legislatures considered psychedelic-related bills in the 2025–2026 sessions, most focused on regulated therapeutic access rather than broad legalization.

The International Framework

The global legal status of psychedelics was largely established by a single instrument: the United Nations Convention on Psychotropic Substances (1971). Drafted in the aftermath of the 1960s counterculture and the American Controlled Substances Act, the Convention placed LSD, psilocybin, and mescaline in Schedule I — MDMA was added in 1986 — the most restrictive category — obligating signatory states to criminalise their manufacture, distribution, and possession.

This framework was not the product of pharmacological evidence. It was a political settlement driven primarily by the United States. Its legacy — fifty years of research suppression, mass incarceration, and disproportionate harm to Black and Indigenous communities — is increasingly acknowledged even by mainstream institutions.

Decriminalisation vs. Legalisation — A Critical Distinction

Decriminalisation means that personal possession or use of a substance is no longer treated as a criminal offence — typically resulting in civil penalties, fines, or diversion to health services rather than arrest and prosecution. It does not make the substance legal to produce, sell, or distribute. Decriminalisation primarily reduces individual harm from enforcement; it does not create a regulated supply chain or legal commercial market.

Legalisation means that specified activities involving the substance — production, distribution, sale, use — are permitted under a regulatory framework. It may be limited (e.g., legalisation for therapeutic use only) or broader (e.g., regulated recreational markets, as with cannabis in Canada).

Much media coverage conflates these concepts, creating public confusion about what specific reforms actually mean for individuals.

Canada

Canada is one of the most progressive jurisdictions in the world for psychedelic access, though "progressive" here means relative to a very restrictive baseline.

Federal scheduling

Psilocybin and psilocin are Schedule III substances under Canada's Controlled Drugs and Substances Act (CDSA). LSD, MDMA, mescaline, DMT, and ketamine are Schedule III or I. Possession, production, and distribution of scheduled substances without authorisation is a criminal offence.

Section 56 exemptions

Under Section 56 of the CDSA, the Minister of Health may grant exemptions from the application of specified provisions for medical, scientific, or other reasons. Since 2020, Health Canada has granted Section 56 exemptions to allow a small number of Canadians — primarily patients with terminal illness and end-of-life distress — to access psilocybin-assisted therapy. As of 2024, exemptions have also been extended to allow therapists in training to have personal experience with psilocybin.

Special Access Program (SAP)

Health Canada's Special Access Program allows healthcare practitioners to request access to restricted substances — including psilocybin and MDMA — for patients with serious or life-threatening conditions when conventional treatments have failed. Applications are reviewed case-by-case.

Decriminalisation in British Columbia

In January 2023, British Columbia became the first Canadian province to pilot a decriminalisation model for small amounts of personal possession of most controlled substances — including psychedelics — as part of its response to the opioid crisis. This pilot was subsequently paused in April 2024 due to concerns about public drug use, but the policy trajectory reflects a broader shift in harm reduction orientation at the provincial level.

Indigenous ceremonial use

The legal status of Indigenous ceremonial use of psilocybin mushrooms, ayahuasca, and other plant medicines in Canada is complex and not fully resolved. Section 35 of the Constitution Act (1982) protects Aboriginal rights, and courts have recognised that this can include rights to engage in ceremonial practices involving controlled substances — though the contours of this protection are still being defined.

United States

In the United States, psilocybin, LSD, and most classical psychedelics are Schedule I federal substances — with no currently accepted medical use and high abuse potential according to federal law, a classification that many researchers argue is pharmacologically unjustifiable. This federal status coexists with a patchwork of state and municipal reforms.

Oregon became the first state to legalise regulated psilocybin services in 2020 (Measure 109), with licensed service centres beginning operation in 2023. Colorado legalised "natural medicine" services including psilocybin and mescaline (excluding peyote) under Proposition 122 in 2022, with healing centers licensed from 2025. New Mexico passed the Medical Psilocybin Act in 2025 — the first state to create a psilocybin therapy program through the legislature rather than a ballot initiative — and New Jersey signed a hospital-based psilocybin therapy pilot into law in early 2026. A growing number of cities — including Denver, Oakland, Santa Cruz, and Seattle — have decriminalised personal possession of psilocybin and in some cases other psychedelics.

MDMA-assisted therapy for PTSD reached FDA review in 2024 following two positive Phase 3 trials, but the FDA declined approval in August 2024 and requested an additional trial. The path to federal approval continues, but on a longer timeline than advocates had hoped.

Other Jurisdictions

Netherlands. Psilocybin mushrooms (paddos) were banned in 2008, but psilocybin truffles (sclerotia) remain legal to sell and possess. The Netherlands hosts a significant retreat industry built on this distinction.

Jamaica and Cayman Islands. Psilocybin mushrooms are not scheduled under Jamaican law, making Jamaica a significant destination for retreat tourism operating in a legal grey zone.

Brazil and Peru. Ayahuasca is legal in Brazil (since 2010, for ceremonial use) and unregulated in Peru, where a significant retreat economy has developed. Both countries are sources of significant Indigenous rights concerns regarding the commercialisation of ceremonial practice.

Portugal. Portugal's 2001 decriminalisation of personal possession of all drugs — including psychedelics — is the most comprehensive drug decriminalisation policy in the world and has been extensively studied as a public health model.

Legal Implications for Facilitation

In Canada and most jurisdictions, providing psychedelic substances to another person — even in a therapeutic context, even without payment — constitutes trafficking under the CDSA or equivalent legislation, carrying significantly greater penalties than personal possession. Legal facilitation currently requires operating within one of the formal access pathways (SAP, Section 56 exemption) or within an Indigenous ceremonial context with appropriate legal grounding.

This legal reality means that the vast majority of underground facilitation and therapy occurring in Canada is technically criminal, regardless of the therapeutic intent or competence of the facilitator. This is a policy problem that advocates are actively working to address through regulatory reform.